Horn Howard sold $156K of RARE
Horn Howard (Chief Financial Officer) sold 4,698 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $33.13 ($0.16M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure updates the insider trading record but does not, by itself, indicate a new fundamental development for Ultragenyx.
Market read
Traders may treat this as routine insider activity; absent other catalysts, it is unlikely to drive a directional trade.
What to watch
The article provides only the sale details; it does not include any concurrent company news (earnings, guidance, trial updates) that would contextualize the sale.
Background
This is an SEC Form 4 insider transaction for Ultragenyx Pharmaceutical Inc., reported by CFO Horn Howard.
Ticker impact
Horn Howard, Ultragenyx’s CFO, sold 4,698 shares in an open-market transaction under a 10b5-1 plan, totaling $155,644.74.
Low likelihood of a near-term price move driven solely by this Form 4 sale.
The filing is a disclosed insider sale (not a buy), but it is explicitly under a Rule 10b5-1 plan, which reduces the immediacy/interpretability of the signal.
Market effects
Minimal—this is company-specific insider transaction disclosure with no stated operational/regulatory/clinical catalyst.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with valuation or liquidity needs; traders may still watch for follow-on insider activity.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
RARE; subject of the Form 4 insider sale disclosure.
- insiderHorn Howard
CFO who executed an open-market sale under a Rule 10b5-1 plan.
